Rigel Pharmaceuticals, Inc. (RIGL) Earnings History
Annual and quarterly earnings data from 1999 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 89.6% | 13.5% | 9.8% |
| 2023 | 93.9% | -17.5% | -21.5% |
| 2022 | 98.5% | -46.2% | -48.7% |
| 2021 | 99.3% | -8.4% | -12.0% |
| 2020 | 99.2% | -26.7% | -27.4% |
Download Data
Export RIGL earnings history in CSV or JSON format
Free sign-in required to download data
Rigel Pharmaceuticals, Inc. (RIGL) Earnings Overview
As of March 1, 2026, Rigel Pharmaceuticals, Inc. (RIGL) reported trailing twelve-month net income of $113M, reflecting +1.7% year-over-year growth. The company earned $5.91 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, RIGL's historical earnings data spans multiple years. The company achieved its highest annual net income of $38M in fiscal 2010.
Rigel Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 0.9%, operating margin of 0.1%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), RIGL has room to improve margins relative to the peer group. Compare RIGL vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $17M | +169.7% | $24M | $0.99 | 9.8% | 13.5% |
| 2023 | -$25M | +57.2% | -$20M | $-1.44 | -21.5% | -17.5% |
| 2022 | -$59M | -227.0% | -$56M | $-3.40 | -48.7% | -46.2% |
| 2021 | -$18M | +39.8% | -$12M | $-1.10 | -12.0% | -8.4% |
| 2020 | -$30M | +55.3% | -$29M | $-1.80 | -27.4% | -26.7% |
| 2019 | -$67M | +5.6% | -$69M | $-4.00 | -112.2% | -116.5% |
| 2018 | -$70M | +9.6% | -$73M | $-4.40 | -158.3% | -163.3% |
| 2017 | -$78M | -12.7% | -$80M | $-6.17 | -1739.3% | -1775.6% |
| 2016 | -$69M | -34.5% | -$70M | $-7.33 | -339.6% | -342.2% |
| 2015 | -$51M | +43.4% | -$52M | $-5.82 | -178.1% | -179.1% |
See RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare RIGL vs AGIO
See how RIGL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is RIGL growing earnings?
RIGL EPS of $5.91 reflects slowing growth at +1.7%, below the 5-year CAGR of N/A. TTM net income is $113M. Expansion rate has moderated.
What are RIGL's profit margins?
Rigel Pharmaceuticals, Inc. net margin is +0.1%, with operating margin at +0.1%. Below-average margins reflect competitive or cost pressures.
How consistent are RIGL's earnings?
RIGL earnings data spans 1999-2024. The current earnings trend is +1.7% YoY. Historical data enables comparison across business cycles.